NetworkNewsBreaks – Mizuho Securities Reiterates ‘Buy’ Rating on NovoCure Limited (NASDAQ: NVCR)
Mizuho Securities USA LLC has reiterated its ‘Buy’ rating and issued a price target of $51 on shares of NovoCure Limited’s (NASDAQ: NVCR) stock. NovoCure is an oncology company engaged in the development of an incomparable cancer treatment employing tumor treating fields. This proprietary therapy works by using electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Mizuho’s analysis follows shortly after the company’s recently reported financial results for the three months ended September 30, 2018. Among other highlights from the earnings report, the company reported net revenues for the third quarter 2018 of $64.8 million,…







